Citation:Schröder FH, Kurth KH, Fosså SD, Hoekstra W, Karthaus PP, et al 2004

Citation

Schröder FH, Kurth KH, Fosså SD, Hoekstra W, Karthaus PP, et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study. J Urol 2004 Sep;172(3):923-7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15310999.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Are there differences between the different hormone therapy methods in the pattern and severity of toxicity effects for non metastatic disease?
2. Is any one hormone therapy (androgen ablation) superior to another when given in the first line setting in terms of survival in metastatic disease?
3. What should be done for patients with locally advanced disease who are not suitable candidates for surgery or radiotherapy – primary androgen deprivation at diagnosis or wait until clinical progression (localized or metastatic) - Timing?
4. What should be done for patients with locally advanced disease who are not suitable candidates for surgery or radiotherapy – primary androgen deprivation at diagnosis or wait until clinical progression (localized or metastatic)?